GLP-1 RA users was associated with significantly less cognitive decline than treatment as usual, where participants could take up to two non-GLP-1 RA diabetes medications (RR = 0.86[0.79, 0.95]).50 This evidence concerns the gene GLP1R and diabetes mellitus.